Sven Potelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sven Potelle has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- François Foulquier
Univ. Lille, CNRS, UMR 8576 – UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, FR
7 shared publications Eudoxie Dulary
CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Université de Lille, Lille F-59000, France and the LIA GLYCOLAB4CDG France/ Belgium (International Associated Laboratory "Laboratory for the Research on Congenital Disorders of Glycosylation - from cellular mechanisms to cure")
4 shared publications- Marie-Ange Krzewinski-Recchi
Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F- 59000, Lille, France
4 shared publications Willy Morelle
CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Université de Lille, Lille F-59000, France and the LIA GLYCOLAB4CDG France/ Belgium (International Associated Laboratory "Laboratory for the Research on Congenital Disorders of Glycosylation - from cellular mechanisms to cure")
4 shared publicationsDorothée Vicogne
CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Université de Lille, Lille F-59000, France and the LIA GLYCOLAB4CDG France/ Belgium (International Associated Laboratory "Laboratory for the Research on Congenital Disorders of Glycosylation - from cellular mechanisms to cure")
3 shared publicationsGeoffroy de Bettignies
Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F- 59000, Lille, France
3 shared publications
Latest Publications
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
TMEM165 : a new regulator of Golgi Mn2+ homeostasis involved in congenital disorders of glycosylation
TMEM165 : un nouvel acteur de la régulation de l’homéostasie golgienne du Mn2+, impliqué dans les anomalies congénitales de la glycosylation: Les anomalies congénitales de la glycosylation (CDG) sont des maladies génétiques rares caractérisées par une glycosylation aberrante des protéines. Récemment, un sous-groupe de CDG dues à des perturbations de l'homéostasie de l’appareil de Golgi a fait son apparition. En 2012, notre équipe a identifié TMEM165 comme étant une protéine golgienne impliquée dans les CDG, mais dont les fonctions biologiques et cellulaires demeurent inconnues. Au cours de mon doctorat, nous avons montré que l'homéostasie golgienne du Mn2+ était altérée en absence de TMEM165. Alors que de forts défauts de glycosylation, en particulier des défauts de galactosylation, ont été observés dans des cellules déficientes en TMEM165, nous avons découvert que la supplémentation en Mn2+ était suffisante pour rétablir une glycosylation normale. De façon intéressante, nous avons également démontré que ce défaut de glycosylation pouvait également être supprimé par une supplémentation en galactose. Fort de cette observation, la supplémentation orale en galactose a été testée chez des patients déficients en TMEM165 et il a été prouvé que ce traitement améliorait significativement les paramètres biochimiques et cliniques. De plus, nous avons mis en évidence que la stabilité de TMEM165 était altérée en présence d'une concentration élevée de Mn2+. En effet, nous avons montré que l'exposition à des concentrations élevées de Mn2+ entraînait une dégradation lysosomale rapide de TMEM165. Dans l'ensemble, notre étude montre que TMEM165 est (i) un acteur clé de la glycosylation golgienne en régulant finement l'homéostasie du Mn2+ et (ii) une nouvelle protéine de l’appareil de Golgi sensible au manganèse.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
TMEM165 : a new regulator of Golgi Mn2+ homeostasis involved in congenital disorders of glycosylation
TMEM165 : un nouvel acteur de la régulation de l’homéostasie golgienne du Mn2+, impliqué dans les anomalies congénitales de la glycosylation: Les anomalies congénitales de la glycosylation (CDG) sont des maladies génétiques rares caractérisées par une glycosylation aberrante des protéines. Récemment, un sous-groupe de CDG dues à des perturbations de l'homéostasie de l’appareil de Golgi a fait son apparition. En 2012, notre équipe a identifié TMEM165 comme étant une protéine golgienne impliquée dans les CDG, mais dont les fonctions biologiques et cellulaires demeurent inconnues. Au cours de mon doctorat, nous avons montré que l'homéostasie golgienne du Mn2+ était altérée en absence de TMEM165. Alors que de forts défauts de glycosylation, en particulier des défauts de galactosylation, ont été observés dans des cellules déficientes en TMEM165, nous avons découvert que la supplémentation en Mn2+ était suffisante pour rétablir une glycosylation normale. De façon intéressante, nous avons également démontré que ce défaut de glycosylation pouvait également être supprimé par une supplémentation en galactose. Fort de cette observation, la supplémentation orale en galactose a été testée chez des patients déficients en TMEM165 et il a été prouvé que ce traitement améliorait significativement les paramètres biochimiques et cliniques. De plus, nous avons mis en évidence que la stabilité de TMEM165 était altérée en présence d'une concentration élevée de Mn2+. En effet, nous avons montré que l'exposition à des concentrations élevées de Mn2+ entraînait une dégradation lysosomale rapide de TMEM165. Dans l'ensemble, notre étude montre que TMEM165 est (i) un acteur clé de la glycosylation golgienne en régulant finement l'homéostasie du Mn2+ et (ii) une nouvelle protéine de l’appareil de Golgi sensible au manganèse.
- Open Access
- 20 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 218-226
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia
Living cells depend on an intricate network of chemical reactions catalysed by enzymes, which sometimes make mistakes that lead to their inactivation. Here we report a metabolite-based mechanism for preserving enzyme function in an unfavourable environment. We found that the enzyme TGDS produces UDP-4-keto-6-deoxyglucose, a mimic of the reaction intermediate of the enzyme UXS1, which regenerates the essential cofactor NAD+ within the catalytic pocket of UXS1 by completing its catalytic cycle. Thus, the production of an ‘enzyme-rescue metabolite’ by TGDS represents a mechanism for maintaining the activity of an enzyme in a subcellular compartment where NAD+ is scarce. Using a combination of in vitro and in vivo studies, we demonstrate that the inability to produce sufficient amounts of this enzyme-rescue metabolite leads to the inactivation of UXS1, impairing the synthesis of specific glycans that are crucial for skeletal development. This provides an explanation for the development of the hereditary skeletal disorder Catel–Manzke syndrome in individuals with TGDS deficiency. Defects in similar protective layers might contribute to metabolic changes in other diseases that cannot be explained with common concepts in metabolic biochemistry.
- 20 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 218-226
Open AccessA missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia
Living cells depend on an intricate network of chemical reactions catalysed by enzymes, which sometimes make mistakes that lead to their inactivation. Here we report a metabolite-based mechanism for preserving enzyme function in an unfavourable environment. We found that the enzyme TGDS produces UDP-4-keto-6-deoxyglucose, a mimic of the reaction intermediate of the enzyme UXS1, which regenerates the essential cofactor NAD+ within the catalytic pocket of UXS1 by completing its catalytic cycle. Thus, the production of an ‘enzyme-rescue metabolite’ by TGDS represents a mechanism for maintaining the activity of an enzyme in a subcellular compartment where NAD+ is scarce. Using a combination of in vitro and in vivo studies, we demonstrate that the inability to produce sufficient amounts of this enzyme-rescue metabolite leads to the inactivation of UXS1, impairing the synthesis of specific glycans that are crucial for skeletal development. This provides an explanation for the development of the hereditary skeletal disorder Catel–Manzke syndrome in individuals with TGDS deficiency. Defects in similar protective layers might contribute to metabolic changes in other diseases that cannot be explained with common concepts in metabolic biochemistry.
- Open Access
- 19 April 2017
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 474 (9) , 1481-1493
Manganese-induced turnover of TMEM165
TMEM165 deficiencies lead to one of the congenital disorders of glycosylation (CDG), a group of inherited diseases where the glycosylation process is altered. We recently demonstrated that the Golgi glycosylation defect due to TMEM165 deficiency resulted from a Golgi manganese homeostasis defect and that Mn2+ supplementation was sufficient to rescue normal glycosylation. In the present paper, we highlight TMEM165 as a novel Golgi protein sensitive to manganese. When cells were exposed to high Mn2+ concentrations, TMEM165 was degraded in lysosomes. Remarkably, while the variant R126H was sensitive upon manganese exposure, the variant E108G, recently identified in a novel TMEM165-CDG patient, was found to be insensitive. We also showed that the E108G mutation did not abolish the function of TMEM165 in Golgi glycosylation. Altogether, the present study identified the Golgi protein TMEM165 as a novel Mn2+-sensitive protein in mammalian cells and pointed to the crucial importance of the glutamic acid (E108) in the cytosolic ELGDK motif in Mn2+-induced degradation of TMEM165.
- 19 April 2017
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 474 (9) , 1481-1493
Open AccessManganese-induced turnover of TMEM165
TMEM165 deficiencies lead to one of the congenital disorders of glycosylation (CDG), a group of inherited diseases where the glycosylation process is altered. We recently demonstrated that the Golgi glycosylation defect due to TMEM165 deficiency resulted from a Golgi manganese homeostasis defect and that Mn2+ supplementation was sufficient to rescue normal glycosylation. In the present paper, we highlight TMEM165 as a novel Golgi protein sensitive to manganese. When cells were exposed to high Mn2+ concentrations, TMEM165 was degraded in lysosomes. Remarkably, while the variant R126H was sensitive upon manganese exposure, the variant E108G, recently identified in a novel TMEM165-CDG patient, was found to be insensitive. We also showed that the E108G mutation did not abolish the function of TMEM165 in Golgi glycosylation. Altogether, the present study identified the Golgi protein TMEM165 as a novel Mn2+-sensitive protein in mammalian cells and pointed to the crucial importance of the glutamic acid (E108) in the cytosolic ELGDK motif in Mn2+-induced degradation of TMEM165.
- 1 April 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1861 (4) , 737-748
Evidence for splice transcript variants of TMEM165, a gene involved in CDG
- 1 April 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1861 (4) , 737-748
Evidence for splice transcript variants of TMEM165, a gene involved in CDG
- 1 April 2017
- Published by Elsevier in Tissue and Cell
- Vol. 49 (2) , 150-156
TMEM165 deficiencies in Congenital Disorders of Glycosylation type II (CDG-II): Clues and evidences for roles of the protein in Golgi functions and ion homeostasis
- 1 April 2017
- Published by Elsevier in Tissue and Cell
- Vol. 49 (2) , 150-156
TMEM165 deficiencies in Congenital Disorders of Glycosylation type II (CDG-II): Clues and evidences for roles of the protein in Golgi functions and ion homeostasis
- 9 January 2017
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (4) , 1375-1386
Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects
Context: TMEM165 deficiency is a severe multisystem disease that manifests with metabolic, endocrine, and skeletal involvement. It leads to one type of congenital disorders of glycosylation (CDG), a rapidly growing group of inherited diseases in which the glycosylation process is altered. Patients have decreased galactosylation by serum glycan analysis. There are >100 CDGs, but only specific types are treatable. Objective: Galactose has been shown to be beneficial in other CDG types with abnormal galactosylation. The aim of this study was to characterize the effects of galactose supplementation on Golgi glycosylation in TMEM165-depleted HEK293 cells, as well as in 2 patients with TMEM165-CDG and in their cultured skin fibroblast cells. Design and Setting: Glycosylation was assessed by mass spectrometry, western blot analysis, and transferrin isoelectrofocusing. Patients and Interventions: Both unrelated patients with TMEM165-CDG with the same deep intronic homozygous mutation (c.792+182G>A) were allocated to receive d-galactose in a daily dose of 1 g/kg. Results: We analyzed N-linked glycans and glycolipids in knockout TMEM165 HEK293 cells, revealing severe hypogalactosylation and GalNAc transfer defects. Although these defects were completely corrected by the addition of Mn2+, we demonstrated that the observed N-glycosylation defect could also be overcome by galactose supplementation. We then demonstrated that oral galactose supplementation in patients with TMEM165-deficient CDG improved biochemical and clinical parameters, including a substantial increase in the negatively charged transferrin isoforms, and a decrease in hypogalactosylated total N-glycan structures, endocrine function, and coagulation parameters. Conclusion: To our knowledge, this is the first description of abnormal glycosylation of lipids in the TMEM165 defect and the first report of successful dietary treatment in TMEM165 deficiency. We recommend the use of oral d-galactose therapy in TMEM165-CDG.
- 9 January 2017
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (4) , 1375-1386
Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects
Context: TMEM165 deficiency is a severe multisystem disease that manifests with metabolic, endocrine, and skeletal involvement. It leads to one type of congenital disorders of glycosylation (CDG), a rapidly growing group of inherited diseases in which the glycosylation process is altered. Patients have decreased galactosylation by serum glycan analysis. There are >100 CDGs, but only specific types are treatable. Objective: Galactose has been shown to be beneficial in other CDG types with abnormal galactosylation. The aim of this study was to characterize the effects of galactose supplementation on Golgi glycosylation in TMEM165-depleted HEK293 cells, as well as in 2 patients with TMEM165-CDG and in their cultured skin fibroblast cells. Design and Setting: Glycosylation was assessed by mass spectrometry, western blot analysis, and transferrin isoelectrofocusing. Patients and Interventions: Both unrelated patients with TMEM165-CDG with the same deep intronic homozygous mutation (c.792+182G>A) were allocated to receive d-galactose in a daily dose of 1 g/kg. Results: We analyzed N-linked glycans and glycolipids in knockout TMEM165 HEK293 cells, revealing severe hypogalactosylation and GalNAc transfer defects. Although these defects were completely corrected by the addition of Mn2+, we demonstrated that the observed N-glycosylation defect could also be overcome by galactose supplementation. We then demonstrated that oral galactose supplementation in patients with TMEM165-deficient CDG improved biochemical and clinical parameters, including a substantial increase in the negatively charged transferrin isoforms, and a decrease in hypogalactosylated total N-glycan structures, endocrine function, and coagulation parameters. Conclusion: To our knowledge, this is the first description of abnormal glycosylation of lipids in the TMEM165 defect and the first report of successful dietary treatment in TMEM165 deficiency. We recommend the use of oral d-galactose therapy in TMEM165-CDG.
- Open Access
- 1 February 2016
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 25 (8) , 1489-1500
Glycosylation abnormalities in Gdt1p/TMEM165 deficient cells result from a defect in Golgi manganese homeostasis
Congenital disorders of glycosylation (CDG) are severe inherited diseases in which aberrant protein glycosylation is a hallmark. From this genetically and clinically heterogenous group, a significant subgroup due to Golgi homeostasis defects is emerging. We previously identified TMEM165 as a Golgi protein involved in CDG. Extremely conserved in the eukaryotic reign, the molecular mechanism by which TMEM165 deficiencies lead to Golgi glycosylation abnormalities is enigmatic. As GDT1 is the ortholog of TMEM165 in yeast, both gdt1Δ null mutant yeasts and TMEM165 depleted cells were used. We highlighted that the observed Golgi glycosylation defects due to Gdt1p/TMEM165 deficiency result from Golgi manganese homeostasis defect. We discovered that in both yeasts and mammalian Gdt1p/TMEM165-deficient cells, Mn2+ supplementation could restore a normal glycosylation. We also showed that the GPP130 Mn2+ sensitivity was altered in TMEM165 depleted cells. This study not only provides novel insights into the molecular causes of glycosylation defects observed in TMEM165-deficient cells but also suggest that TMEM165 is a key determinant for the regulation of Golgi Mn2+ homeostasis.
- 1 February 2016
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 25 (8) , 1489-1500
Open AccessGlycosylation abnormalities in Gdt1p/TMEM165 deficient cells result from a defect in Golgi manganese homeostasis
Congenital disorders of glycosylation (CDG) are severe inherited diseases in which aberrant protein glycosylation is a hallmark. From this genetically and clinically heterogenous group, a significant subgroup due to Golgi homeostasis defects is emerging. We previously identified TMEM165 as a Golgi protein involved in CDG. Extremely conserved in the eukaryotic reign, the molecular mechanism by which TMEM165 deficiencies lead to Golgi glycosylation abnormalities is enigmatic. As GDT1 is the ortholog of TMEM165 in yeast, both gdt1Δ null mutant yeasts and TMEM165 depleted cells were used. We highlighted that the observed Golgi glycosylation defects due to Gdt1p/TMEM165 deficiency result from Golgi manganese homeostasis defect. We discovered that in both yeasts and mammalian Gdt1p/TMEM165-deficient cells, Mn2+ supplementation could restore a normal glycosylation. We also showed that the GPP130 Mn2+ sensitivity was altered in TMEM165 depleted cells. This study not only provides novel insights into the molecular causes of glycosylation defects observed in TMEM165-deficient cells but also suggest that TMEM165 is a key determinant for the regulation of Golgi Mn2+ homeostasis.
- 16 December 2015
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (11) , 2318-2321
A sequential bioorthogonal dual strategy: ManNAl and SiaNAl as distinct tools to unravel sialic acid metabolic pathways
Recent methodological developments in metabolic oligosaccharide engineering (MOE) pave the way for tremendous advances in glycobiology. Herein, we propose a Sequential Bioorthogonal Dual Strategy (SBDS) combining the use of two unprotected alkyne-tagged monosaccharide reporters (ManNAl and SiaNAl) with the bioligation of fluorescent probes by copper-catalysed azide–alkyne cycloaddition (CuAAC). With SBDS, we are able to shed light on trafficking and cellular uptake mechanisms of sialic acid. Using their corresponding analogues, we visualized that SiaNAl enters via endocytosis, whereas its biosynthetic intermediate ManNAl uptake is mediated by a yet unknown but specific plasma membrane transporter. Sialin, a lysosomal protein, is shown to be crucial for the export of exogenous sialic acid from lysosomes to the cytosol. Metabolic labeling with alkyne-tagged derivatives of N-acetylneuraminic acid (Neu5Ac) or N-acetylmannosamine (ManNAc) could thus be used to follow endocytosis in physiological vs. pathological conditions.
- 16 December 2015
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (11) , 2318-2321
A sequential bioorthogonal dual strategy: ManNAl and SiaNAl as distinct tools to unravel sialic acid metabolic pathways
Recent methodological developments in metabolic oligosaccharide engineering (MOE) pave the way for tremendous advances in glycobiology. Herein, we propose a Sequential Bioorthogonal Dual Strategy (SBDS) combining the use of two unprotected alkyne-tagged monosaccharide reporters (ManNAl and SiaNAl) with the bioligation of fluorescent probes by copper-catalysed azide–alkyne cycloaddition (CuAAC). With SBDS, we are able to shed light on trafficking and cellular uptake mechanisms of sialic acid. Using their corresponding analogues, we visualized that SiaNAl enters via endocytosis, whereas its biosynthetic intermediate ManNAl uptake is mediated by a yet unknown but specific plasma membrane transporter. Sialin, a lysosomal protein, is shown to be crucial for the export of exogenous sialic acid from lysosomes to the cytosol. Metabolic labeling with alkyne-tagged derivatives of N-acetylneuraminic acid (Neu5Ac) or N-acetylmannosamine (ManNAc) could thus be used to follow endocytosis in physiological vs. pathological conditions.
- 13 May 2015
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 38 (4) , 741-751
Golgi post‐translational modifications and associated diseases
For non specialists, Golgi is a very well known subcellular compartment involved in secretion and correct targeting of soluble and transmembrane proteins. Nevertheless, Golgi is also specifically involved in many different and diverse post‐translational modifications. Through its diverse functions, Golgi is not only able to modify secreted and transmembrane proteins but also cytoplasmic proteins. The Golgi apparatus research field is so broad that an exhaustive review of this organelle is not doable here. The goal of this review is to cover the main post‐translational modifications occurring at the Golgi level and present the identified associated diseases.
- 13 May 2015
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 38 (4) , 741-751
Golgi post‐translational modifications and associated diseases
For non specialists, Golgi is a very well known subcellular compartment involved in secretion and correct targeting of soluble and transmembrane proteins. Nevertheless, Golgi is also specifically involved in many different and diverse post‐translational modifications. Through its diverse functions, Golgi is not only able to modify secreted and transmembrane proteins but also cytoplasmic proteins. The Golgi apparatus research field is so broad that an exhaustive review of this organelle is not doable here. The goal of this review is to cover the main post‐translational modifications occurring at the Golgi level and present the identified associated diseases.